Pathos AI Secures $365 Million in Series D Funding to Advance AI-Powered Oncology Drug Development

Pathos AI Secures Massive Funding for AI-Driven Oncology Research

Pathos AI, a startup at the forefront of AI-powered drug development, has successfully closed a $365 million Series D funding round, propelling its valuation to approximately $1.6 billion 1

1

2

2

. This significant investment marks a pivotal moment for the company as it seeks to revolutionize oncology drug development through advanced artificial intelligence.

The PathOS Platform and AI Foundation Model

At the heart of Pathos AI's innovation is its PathOS platform, which hosts petabytes of oncology and genomic data. This platform enables pharmaceutical scientists to analyze vast amounts of information, potentially improving the design and execution of clinical trials for new drugs 1

1

.

Building on this foundation, Pathos is now developing what it describes as the largest AI foundation model for oncology research. This multimodal model is designed to process clinical, molecular, and imaging data, promising to enhance various aspects of drug development, including:

1. Clinical asset selection
2. Clinical trial design
3. Biomarker discovery
4. Therapeutic innovation 2

   2

Current Clinical Trials and Future Plans

Pathos is currently conducting trials for two cancer drugs licensed from Novo Nordisk AS and Prelude Therapeutics Inc. The newly secured funding will finance these ongoing clinical studies and support the development of their ambitious AI model 1

1

.

Strategic Partnerships

In April, Pathos formed strategic partnerships with pharmaceutical giant AstraZeneca plc and healthcare technology company Tempus AI Inc. These collaborations, valued at $200 million in data licensing and model development agreements, will provide Pathos with anonymized oncology data to train its AI model 1

1

.

Industry Context and Competition

Pathos AI is not alone in its pursuit of AI-driven medical research. Tech giants like Google and Microsoft have also entered the field:

• Google released TxGemma, a series of language models for drug development research
• Microsoft introduced TamGen, an algorithm for automating molecule discovery with therapeutic potential 1

  1

Leadership Vision

Iker Huerga, CEO of Pathos AI, emphasized the company's mission: "Pathos was founded to transform drug development by harnessing the full potential of multimodal data and AI. With this financing, we're building one of the most advanced AI engines, designed to accelerate development, deepen clinical insight, and ensure the right therapies reach the patients who need them most." 1

1

2

2

As Pathos AI moves forward with its ambitious plans, the biotech industry watches closely to see how this significant investment and advanced AI technology will shape the future of oncology drug development and, ultimately, impact patient outcomes.